Dear John,

ICYMI, Jihye Han of Brigham and Women's Hospital and Harvard University appeared on A Health Podyssey to discuss her recent paper that takes a closer look at the regulatory treatments for first-in-class drugs and how those differ between the US and Europe.

Today's Featured Articles

First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe

Jihye Han and Aaron S. Kesselheim

An Argument For A New Medicare Prospective Payment System Methodology For Certified Community Behavioral Health Clinics

Joshua Pearson

More on FDA Approvals Process

FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time

Kathleen L. Miller et al. (July 2024)

Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey

Sanket S. Dhruva et al. (January 2024)

Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs

C. Joseph Ross Daval et al. (May 2022)

LIVE! with Yashaswini Singh

Join us for a live taping of A Health Podyssey on March 12 with Yashaswini Singh about her upcoming paper in the March 2025 edition of Health Affairs.

Host Rob Lott and Singh will take questions from the audience as well.
 

This event is free and open to all.

Celebrating Women's History Month

This Women's History Month, we're elevating women who work to advance health equity and policy.

In a December 2024 article, Anne B. Martin and coauthors assess the trends in economic and health sector growth during 2020–23.

They note the acceleration in total national health spending growth in 2023 was primarily driven by faster growth in the three largest categories:

• Hospital care
• Physician and clinical services
• Retail prescription drugs